Nantahala Capital Management

What Nantahala Capital Management does

Nantahala Capital Management is a fundamentally-driven alternative investment firm founded in 2004 by Wil Harkey, with Dan Mack joining as co-portfolio manager in 2007. The firm invests primarily in micro-cap equities — issuers with market capitalizations under $2.5 billion — using a market-neutral, long/short strategy designed to maintain low correlation to broader equity benchmarks. It serves institutional investors and high-net-worth individuals as limited partners.

The firm deploys capital across PIPEs (Private Investment in Public Equity), private placements, and public offerings, applying a private-equity-style underwriting approach with multi-year holding periods. Recent transaction activity shows a pronounced tilt toward healthcare and biotechnology, including clinical-stage oncology, cell and gene therapy, RNA editing, medical devices, and specialty pharmaceuticals. The firm has repeatedly assumed lead-investor roles in structured financings (Cellectar Biosciences, Envoy Medical) and has participated in event-driven situations outside healthcare (Fossil Group restructuring alongside HG Vora). It also files 13G/13D disclosures reflecting activist-adjacent positioning (Opus Genetics at 6.51%).

The firm is privately held, headquartered in New Canaan, Connecticut, with 11–50 employees. It generates revenue through conventional alternative-asset management fee structures — management fees on assets under management plus performance fees on investment returns. The leadership team comprises co-founders Wil Harkey and Dan Mack as Portfolio Managers, Senior Analyst Jonathan Buba (since 2011), and COO Paul Rehm, reflecting 16+ years of co-tenure and a 19+ year track record. No financial statements, AUM, or revenue figures are publicly disclosed, and no proprietary technology platform has been announced.

Name

Nantahala Capital Management

Legal name

Nantahala Capital Management, LLC

Website

https://nantahalapartners.com

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Nantahala Capital Management is a New Canaan, CT-based alternative investment firm founded in 2004 that runs a market-neutral, long/short strategy focused on micro-cap equities under $2.5B for institutional and high-net-worth limited partners.

Ownership category

akta.pro rank

Headquarters

HQ city

New Canaan

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Investment Management Fees: Nantahala generates revenue through traditional alternative investment management fee structures, including management fees on assets under management and performance fees (carried interest) on investment returns. The firm manages diversified portfolios of long and short investment ideas for institutional investors and high net worth individuals.

Go-to-market motion1 record

Distribution channels1 record

Core offering

Nantahala Capital Management is a fundamentally-driven alternative investment firm that invests primarily in micro-cap stocks (companies with market caps under $2.5 billion) across multiple sectors, executing a market-neutral, long/short strategy with low to no equity market exposure and a multi-year investment horizon. The firm manages diversified portfolios of long and short investment ideas and sources opportunities through direct management engagement, private placements, PIPEs, and public offerings, acting as an active capital partner with a PE-style, long-term view.

Product overview

Nantahala Capital Management is a fundamentally-driven alternative investment firm founded in 2004 that invests primarily in micro-cap stocks (companies with less than $2.5 billion market cap) across various sectors. The firm employs a multi-year investment time horizon and aims to maximize risk-adjusted returns and alpha generation through a diversified portfolio of long and short investment ideas with low to no equity market exposure. The investment strategy focuses on small and micro-cap healthcare companies and other underserved market segments. The firm is led by Co-founders Wil Harkey and Dan Mack, who have a 19+ year track record of investing in small and micro-cap companies with a market-neutral approach. Note: This is an investment management firm, not a technology product company.

Differentiator

Problem solved

Functional benefit

Products and services

• Micro-Cap Market-Neutral Long/Short Investment Strategy A fundamentally-driven, market-neutral long/short hedge fund strategy targeting micro-cap stocks (companies under $2.5 billion market cap) across multiple sectors, offered as an alternative investment product to qualified institutional investors and high net worth individuals via direct investor mandates and co-investment opportunities.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Sagamore Hill Capital Management: Multi-strategy alternative investment firm where both Nantahala co-founders previously worked; operates in adjacent small/mid-cap equity and convertible strategies and is the most direct professional lineage comparable.
• Driehaus Capital Management: Small/mid-cap growth-focused active manager that co-invests with Nantahala in biotech PIPEs (Korro Bio); operates a comparable small-cap equity active strategy with similar institutional client base.
• Royce Investment Partners: Long-established small-cap equity specialist manager with a similar fundamental, long-term, small/micro-cap orientation; competes for institutional allocator mandates in the small-cap active equity category.
• Kennedy Capital Management: Small/mid-cap value equity manager targeting mispricings in smaller U.S. companies; highly comparable investment universe and fundamental, long-term approach to Nantahala's strategy.
• Brown Capital Management: Small/mid-cap growth equity manager with a long-term, fundamental, concentrated approach targeting overlooked smaller companies — directly overlapping Nantahala's 'minimally trafficked' micro-cap thesis.
• Eidelman Virant Capital: Micro-cap focused investment manager pursuing a long-term, fundamental strategy in U.S. small/micro-cap equities; operates in the same niche universe with comparable institutional client profile.

Broad incumbents

• Balyasny Asset Management: Multi-strategy global hedge fund that repeatedly co-invests with Nantahala in healthcare PIPEs (Cellectar, LB Pharmaceuticals, Korro Bio, Obsidian); much larger but competes for the same small/micro-cap deal flow.
• Caligan Partners: Healthcare-focused investment firm co-investing alongside Nantahala in Cellectar, LB Pharmaceuticals, and Obsidian Therapeutics deals; directly comparable in healthcare micro-cap thesis.
• Janus Henderson Investors: Large global asset manager that participated alongside Nantahala in the Cellectar $140M financing; while much larger and broader, competes for institutional small-cap and healthcare allocations.

Emerging players

• Venrock Healthcare Capital Partners: Healthcare-focused lead investor that co-leads PIPE deals with Nantahala (e.g., Korro Bio); comparable in targeting clinical-stage biotech but operates as crossover/venture capital rather than public-market hedge fund.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/nantahala-capital-management

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments66 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nantahala Capital Management